CN114134108A - 一种干细胞生物活性组合物及其制备方法 - Google Patents
一种干细胞生物活性组合物及其制备方法 Download PDFInfo
- Publication number
- CN114134108A CN114134108A CN202111441394.0A CN202111441394A CN114134108A CN 114134108 A CN114134108 A CN 114134108A CN 202111441394 A CN202111441394 A CN 202111441394A CN 114134108 A CN114134108 A CN 114134108A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- bioactive
- octacosanol
- epo
- sodium acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960002666 1-octacosanol Drugs 0.000 claims abstract description 20
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 18
- 239000001632 sodium acetate Substances 0.000 claims abstract description 18
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 claims description 9
- 102100024813 Targeting protein for Xklp2 Human genes 0.000 claims description 9
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims description 6
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- -1 PDGF-DD Proteins 0.000 claims description 3
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 238000003501 co-culture Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 238000003757 reverse transcription PCR Methods 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 101150021540 tpx2 gene Proteins 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1305—Adipocytes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种干细胞生物活性组合物及其制备方法，具体涉及医疗领域，包括12.36‑55.86pg/ml 1‑Octacosanol、5.63‑20.14pg/ml EPO、10.36‑36.45pg/ml醋酸钠，本发明通过在组合物中添加醋酸钠，提高干细胞的本身活性，并在组合物中添加1‑Octacosanol，此时在向组合物中添加EPO，红细胞生成的一种糖蛋白，添加的1‑Octacosanol会加快酯化反应，加快形成糖蛋白，形成质量良好的干细胞生物活性组合物。
Description
技术领域
本发明涉及医疗领域，具体涉及一种干细胞生物活性组合物及其制备方法。
背景技术
多年来对干细胞的定义不断进行修正，并从不同的层面上来进行定义。大多数生物学家和医学家认为干细胞是来自于胚胎、胎儿或成人体内具有在一定条件下无限制自我更新与增殖分化能力的一类细胞，能够产生表现型与基因型和自己完全相同的子细胞，也能产生组成机体组织、器官的已特化的细胞，同时还能分化为祖细胞，同时干细胞在存储是需要使用干细胞生物活性组合物。
但是现如今的干细胞生物活性组合物及其制备方法在对干细胞进行存储是，活性不高，而且生产的干细胞生物活性组合物质量不高。
发明内容
为此，本发明提供一种干细胞生物活性组合物及其制备方法，以解决现有技术中的问题。
为了实现上述目的，本发明实施例提供如下技术方案：一种干细胞生物活性组合物，包括1.69-22.24pg/ml EGF、2443.17-4459.43pg/ml bFGF、1.44-134.36pg/ml beta-NGF、1.55-355.14pg/ml VEGF、11.87-159.70pg/ml PDGF-DD、135.79-688.13pg/ml KGF、1176.99-3825.79pg/ml TGF-β1、12.36-55.86pg/ml 1-Octacosanol、5.63-20.14pg/mlEPO、10.36-36.45pg/ml醋酸钠。
进一步地，所述12.36pg/ml 1-Octacosanol、5.63pg/ml EPO、36.45pg/ml醋酸钠。
进一步地，所述55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、10.36pg/ml醋酸钠。
进一步地，所述55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、36.45pg/ml醋酸钠。
进一步地，所述检测方法基于权利要求1-4任一项的系统，步骤如下：
S1：利用培养基，对间充质干细胞和脂肪基质细胞进行非接触式共培养；
S2：并收集间充质干细胞液进行收集，并使用离心机收集上清液；
S3：向上清液中逐次添加EGF、bFGF、beta-NGF、VEGF、PDGF-DD、KGF、TGF-β1、1-Octacosanol、EPO、醋酸钠；
S4：使用RT-PCR检测TPX2基因在乳腺癌组织及癌旁组织中的表达差异使用慢病毒干扰载体建立稳定低表达TPX2蛋白的乳腺癌细胞平板克隆、MTT试验验证TPX2对乳腺癌细胞生长能力的影响流式细胞仪检测敲除TPX2之后对乳腺癌细胞凋亡比率的影响；
S5：之后使用微型振动机将混合液进行性震动混合得到组合物。
本发明实施例具有如下优点：
本发明通过在组合物中添加醋酸钠，提高干细胞的本身活性，并在组合物中添加1-Octacosanol，此时在向组合物中添加EPO，红细胞生成的一种糖蛋白，添加的1-Octacosanol会加快酯化反应，加快形成糖蛋白，形成质量良好的干细胞生物活性组合物。
说明
为了更清楚地说明本发明的实施方式或现有技术中的技术方案，下面将对实施方式或现有技术描述中所需要使用的作简单地介绍。显而易见地，下面描述中的仅仅是示例性的，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据提供的引伸获得其它的实施。
本说明书所绘示的结构、比例、大小等，均仅用以配合说明书所揭示的内容，以供熟悉此技术的人士了解与阅读，并非用以限定本发明可实施的限定条件，故不具技术上的实质意义，任何结构的修饰、比例关系的改变或大小的调整，在不影响本发明所能产生的功效及所能达成的目的下，均应仍落在本发明所揭示的技术内容得能涵盖的范围内。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式，熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
一种干细胞生物活性组合物，包括1.69-22.24pg/ml EGF、2443.17-4459.43pg/mlbFGF、1.44-134.36pg/ml beta-NGF、1.55-355.14pg/m lVEGF、11.87-159.70pg/ml PDGF-DD、135.79-688.13pg/ml KGF、1176.99-3825.79pg/ml TGF-β1、12.36-55.86pg/ml 1-Octacosanol、5.63-20.14pg/ml EPO、10.36-36.45pg/ml醋酸钠。
本发明通过在组合物中添加醋酸钠，提高干细胞的本身活性，并在组合物中添加1-Octacosanol，此时在向组合物中添加EPO，红细胞生成的一种糖蛋白，添加的1-Octacosanol会加快酯化反应，加快形成糖蛋白，形成质量良好的干细胞生物活性组合物。
12.36pg/ml 1-Octacosanol、5.63pg/ml EPO、36.45pg/ml醋酸钠。
该种干细胞生物活性组合物的活性较高，能够匀速产生糖蛋白加快，增加干细胞的存活率。
55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、10.36pg/ml醋酸钠。
该种干细胞生物活性组合物活性较低，干细胞存活率较高。
55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、36.45pg/ml醋酸钠。
该种干细胞生物活性组合物活性较高，干细胞存活率较高。
检测方法基于权利要求1-4任一项的系统，步骤如下：
S1：利用培养基，对间充质干细胞和脂肪基质细胞进行非接触式共培养；
S2：并收集间充质干细胞液进行收集，并使用离心机收集上清液；
S3：向上清液中逐次添加EGF、bFGF、beta-NGF、VEGF、PDGF-DD、KGF、TGF-β1、1-Octacosanol、EPO、醋酸钠；
S4：使用RT-PCR检测TPX2基因在乳腺癌组织及癌旁组织中的表达差异使用慢病毒干扰载体建立稳定低表达TPX2蛋白的乳腺癌细胞平板克隆、MTT试验验证TPX2对乳腺癌细胞生长能力的影响流式细胞仪检测敲除TPX2之后对乳腺癌细胞凋亡比率的影响；
S5：之后使用微型振动机将混合液进行性震动混合得到组合物。
虽然，上文中已经用一般性说明及具体实施例对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (5)
1.一种干细胞生物活性组合物，包括1.69-22.24pg/ml EGF、2443.17-4459.43pg/mlbFGF、1.44-134.36pg/ml beta-NGF、1.55-355.14pg/ml VEGF、11.87-159.70pg/ml PDGF-DD、135.79-688.13pg/ml KGF、1176.99-3825.79pg/ml TGF-β1、12.36-55.86pg/ml 1-Octacosanol、5.63-20.14pg/ml EPO、10.36-36.45pg/ml醋酸钠。
2.根据权利要求1所述的一种干细胞生物活性组合物及其制备方法，其特征在于：所述12.36pg/ml 1-Octacosanol、5.63pg/ml EPO、36.45pg/ml醋酸钠。
3.根据权利要求1所述的一种干细胞生物活性组合物及其制备方法，其特征在于：所述55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、10.36pg/ml醋酸钠。
4.根据权利要求1所述的一种干细胞生物活性组合物及其制备方法，其特征在于：所述55.86pg/ml 1-Octacosanol、20.14pg/ml EPO、36.45pg/ml醋酸钠。
5.一种干细胞生物活性组合物的制备方法，其特征在于：所述检测方法基于权利要求1-4任一项的系统，步骤如下：
S1：利用培养基，对间充质干细胞和脂肪基质细胞进行非接触式共培养；
S2：并收集间充质干细胞液进行收集，并使用离心机收集上清液；
S3：向上清液中逐次添加EGF、bFGF、beta-NGF、VEGF、PDGF-DD、KGF、TGF-β1、1-Octacosanol、EPO、醋酸钠；
S4：使用RT-PCR检测TPX2基因在乳腺癌组织及癌旁组织中的表达差异使用慢病毒干扰载体建立稳定低表达TPX2蛋白的乳腺癌细胞平板克隆、MTT试验验证TPX2对乳腺癌细胞生长能力的影响流式细胞仪检测敲除TPX2之后对乳腺癌细胞凋亡比率的影响；
S5：之后使用微型振动机将混合液进行性震动混合得到组合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111441394.0A CN114134108A (zh) | 2021-11-30 | 2021-11-30 | 一种干细胞生物活性组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111441394.0A CN114134108A (zh) | 2021-11-30 | 2021-11-30 | 一种干细胞生物活性组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114134108A true CN114134108A (zh) | 2022-03-04 |
Family
ID=80389655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111441394.0A Pending CN114134108A (zh) | 2021-11-30 | 2021-11-30 | 一种干细胞生物活性组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114134108A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278045A (zh) * | 2005-09-30 | 2008-10-01 | 东菱药品工业株式会社 | 干细胞和/或祖细胞的赋活剂 |
| CN105200008A (zh) * | 2015-10-23 | 2015-12-30 | 新乡医学院 | 干细胞培养基 |
| CN106191127A (zh) * | 2016-02-22 | 2016-12-07 | 华南生物医药研究院 | 干细胞生物活性组合物及其制备方法与应用 |
| US20220061310A1 (en) * | 2018-12-28 | 2022-03-03 | Excel Med, Llc | Method for stabilizing bioactivity of growth factor |
| CN115584342A (zh) * | 2022-09-29 | 2023-01-10 | 中山大学 | 一种延缓间充质干细胞复制性衰老的方法 |
-
2021
- 2021-11-30 CN CN202111441394.0A patent/CN114134108A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278045A (zh) * | 2005-09-30 | 2008-10-01 | 东菱药品工业株式会社 | 干细胞和/或祖细胞的赋活剂 |
| CN105200008A (zh) * | 2015-10-23 | 2015-12-30 | 新乡医学院 | 干细胞培养基 |
| CN106191127A (zh) * | 2016-02-22 | 2016-12-07 | 华南生物医药研究院 | 干细胞生物活性组合物及其制备方法与应用 |
| US20220061310A1 (en) * | 2018-12-28 | 2022-03-03 | Excel Med, Llc | Method for stabilizing bioactivity of growth factor |
| CN115584342A (zh) * | 2022-09-29 | 2023-01-10 | 中山大学 | 一种延缓间充质干细胞复制性衰老的方法 |
Non-Patent Citations (2)
| Title |
|---|
| POUIKLI A等: "Chromatin remodeling due to degradation of citrate carrier impairs osteogenesis of aged mesenchymal stem cells", 《NATURE AGING》, vol. 1, no. 9, pages 810 - 825 * |
| 付清等: "TPX2 shRNA对乳腺癌细胞生长、凋亡、侵袭、迁移能力的影响", 《现代肿瘤医学》, vol. 27, no. 7, pages 1113 - 1117 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105112364B (zh) | 人脂肪间充质干细胞的无血清培养基及其制备方法 | |
| CN112961825B (zh) | 一种无血清培养基及其制备方法 | |
| Newland et al. | Macroporous heparin-based microcarriers allow long-term 3D culture and differentiation of neural precursor cells | |
| CN104805054A (zh) | 干细胞无血清培养基 | |
| CN106834224A (zh) | 一种建立人多能干细胞诱导分化为成熟血细胞的方法 | |
| CN109749993B (zh) | 一种脐带间充质干细胞的培养方法 | |
| CN108184818A (zh) | 一种人胎盘间充质干细胞悬液保护剂 | |
| Rallapalli et al. | Generation of clinical-grade red blood cells from human umbilical cord blood mononuclear cells | |
| Cabral | Ex vivo expansion of hematopoietic stem cells in bioreactors | |
| Andrade et al. | Stem cell bioengineering strategies to widen the therapeutic applications of haematopoietic stem/progenitor cells from umbilical cord blood | |
| CN111944739B (zh) | 一种类器官培养基质材料及其制备方法和应用 | |
| CN114134108A (zh) | 一种干细胞生物活性组合物及其制备方法 | |
| CN111518762A (zh) | 脐带间充质干细胞无血清培养基及其制备方法 | |
| CN110951686A (zh) | 一种造血干细胞体外扩增培养体系和方法 | |
| US20210355444A1 (en) | Method for producing erythroid cells and/or erythrocytes | |
| CN109652377B (zh) | 一种肺癌干细胞的制备方法及应用 | |
| CN109722411B (zh) | 一种促进胚胎干细胞自我更新状态的小分子的应用方法 | |
| Hefei et al. | Morphological characteristics and identification of islet‐like cells derived from rat adipose‐derived stem cells cocultured with pancreas adult stem cells | |
| CN104894059B (zh) | 一型硫氧还蛋白在内皮祖细胞的培养中的应用及内皮祖细胞的培养方法 | |
| CN107460169A (zh) | 维生素c在制备培养基中的用途 | |
| CN109266600A (zh) | 一种成纤维细胞的培养基及利用其培养成纤维细胞的方法 | |
| CN110093314B (zh) | 红细胞脱核培养基及试剂盒 | |
| CN114645013B (zh) | 一种通过物理途径促进干细胞分化的材料及方法 | |
| Varga et al. | Large‐Scale Production of Transfusion‐Ready Red Blood Cells From Induced Pluripotent Stem Cells | |
| CN104818245A (zh) | 一种肝脏干细胞的培养基及培养方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220304 |